EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Chimeric monoclonal anti-CD20 antibody rituximab for the therapy of B-cell non-Hodgkins lymphoma Treatment results and new clinical studies



Chimeric monoclonal anti-CD20 antibody rituximab for the therapy of B-cell non-Hodgkins lymphoma Treatment results and new clinical studies



Annals of Hematology 77(SUPPL 2): S148




(PDF emailed within 1 workday: $29.90)

Accession: 030519602

Download citation: RISBibTeXText



Related references

Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. International Journal of Hematology 74(1): 70-75, 2001

A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkins lymphoma SWOG 9800. Blood 98(11 Part 1): 843a, November 16, 2001

Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 29(3): 473-480, 2002

Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab). Nihon Rinsho. Japanese Journal of Clinical Medicine 60(1): 95-99, 2002

Monoclonal anti-CD20 antibody rituximab for treatment of CD20-positive Hodgkins lymphoma The German experience. Blood 96(11 Part 1): 729a, November 16, 2000

Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Annals of Oncology 11 Suppl 1: 117-121, 2000

Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan. Cancer Chemotherapy and Pharmacology 48(Supplement 1): S85-S90, 2001

Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody. Acta Dermato-Venereologica 81(3): 207-208, 2001

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody in the treatment of non-Hodgkins B-cell lymphoma. Biochemical Society Transactions 25(2): 705-708, 1997

Targeted anti-cancer therapy using a chimeric anti-CD20 antibody in the treatment of non-Hodgkins B cell lymphoma. Immunology 89(SUPPL 1): 19, 1996

Treatment of patients with mantle-cell and aggressive B-cell non-Hodgkins lymphoma using the monoclonal anti-CD20 antibody rituximab Evaluation of safety and response. Blood 94(10 SUPPL 1 PART 2): 270b, Nov 15, 1999

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology 16(8): 2825-2833, 1998

Experimental treatment of human diffuse large B-cell lymphoma xenografts by doxycycline alone or in combination with the anti-CD20 chimeric monoclonal antibody rituximab. American Journal of Hematology 84(6): 387-388, 2009